WO2025257799 - METHODS OF TREATING DRAVET SYNDROME
National phase entry is expected:
Publication Number
WO/2025/257799
Publication Date
18.12.2025
International Application No.
PCT/IB2025/056061
International Filing Date
12.06.2025
Title **
[English]
METHODS OF TREATING DRAVET SYNDROME
[French]
MÉTHODES DE TRAITEMENT DU SYNDROME DE DRAVET
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
AZGHARNEJAD, Mahnaz
PATHI JAGANNATHAM, Naga Venkatesha Murthy
ANDREWS, Jeffrey Scott
Priority Data
63/660,115
14.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3129 | |
| EPO | Filing, Examination, Granting | 23964 | |
| Japan | Filing, Examination, Granting | 3051 | |
| South Korea | Filing, Examination, Granting | 3895 | |
| USA | Filing, Examination, Granting | 10740 |
Total:
44,779
Contact Us
Abstract[English]
The present disclosure relates to using soticlestat or a pharmaceutical acceptable salt thereof as a therapy in a subject with Dravet Syndrome.[French]
La présente divulgation concerne l'utilisation de soticlestat ou d'un sel pharmaceutiquement acceptable de celui-ci en tant que thérapie chez un sujet atteint du syndrome de Dravet.